San Francisco, United States
VeriSIM Life, founded in 2017 and headquartered in the United States, is a compelling player in the Biotechnology and Health Care industries. The company is transforming drug development with BIOiSIM, an AI-driven engine that tackles the inefficiencies and ethical concerns of traditional animal testing. By creating disease-specific biosimulation models, VeriSIM Life allows researchers to simulate drug interactions, thus increasing the speed and accuracy of preclinical testing.
With a Series A funding of $15.00M secured on 01 January 2022, supported by investors like Morpheus Ventures, OCA Ventures, Susa Ventures, The Group Ventures, Serra Ventures, Intel Capital, and Colorcon Ventures, VeriSIM is well-positioned to significantly influence the drug development landscape. By improving the success rate of drugs reaching clinical trials, the company offers an innovative solution that could save millions in development costs, making it a strategic opportunity for investors.
